Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 15, 2025

Primary Completion Date

January 15, 2026

Study Completion Date

April 15, 2026

Conditions

Atopic Dermatitis (AD)Psoriasis (PsO)

Interventions

DRUG

LPX-TI641

Oral administration QD for 28 consecutive days

DRUG

Placebo

Placebo an identical oral formulation without the LPX-TI641.

Trial Locations (1)

Red River Research Partners, Fargo